↑ Rising
Business
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved a first-of-its-kind cholesterol pill from Merck designed to drive cholesterol levels lower than statins.
Pharmaceuticals
16 trends tracked about this subject — the full history, oldest to newest below.
↓ Cooling
Business
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing a deal to acquire psychedelic drugmaker AtaiBeckley, triggering a sharp surge in the company's stock price.
▲ Peaking
Business
🔮 fades ✗
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen faces a mixed market reception as new trial data for its tau-targeting Alzheimer's drug shows both promise and significant unanswered questions.
▲ Peaking
Business
🔮 fades ✓
All eyes on data on Biogen’s tau therapy
Biogen's experimental anti-tau therapy, diranersen, shows promise in slowing cognitive decline for early Alzheimer's patients.
◼ Archived
Business
🔮 fades ✓
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the release of Complete Response Letters (CRLs) after a three-month disclosure freeze, issuing 14 new drug rejection notices.
◼ Archived
Business
🔮 fades ✗
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks, aiming to increase supply chain transparency.
◼ Archived
Business
🔮 fades ✓
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
6 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Ozempic Face, Blindness Claims, And Billions In Potential Damages: The GLP-1 Reckoning
Public scrutiny regarding the mental, physical, and legal implications of GLP-1 receptor agonists intensifies amid reports of potential litigation.
◼ Archived
Business
🔮 fades ✗
AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis share prices plunge following the failure of a key clinical trial for the heart disease drug Wainua.
◼ Archived
Health
🔮 fades ✗
Why experts say peptides just might be the secret to reviving thinning hair
Peptides are gaining attention as a potential solution for thinning hair and general wellness, despite emerging concerns over black-market distribution.
◼ Archived
Business
🔮 fades ✓
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its antibody-drug conjugate (ADC) pipeline through the acquisition of U.K.-based cancer biotech Myricx Bio for up to $1.5 billion.
◼ Archived
Business
🔮 fades ✓
Why breakthrough GLP-1 weight loss pills may be a bad thing for employer insurance coverage
Employers are reconsidering coverage for popular GLP-1 weight loss drugs, leaving patients and insurers in limbo.
◼ Archived
Health
🔮 fades ✓
Eli Lilly and Company (LLY) CEO on How GLP-1s Will Reshape America
Eli Lilly's CEO discusses the potential impact of GLP-1 pills on America's health landscape.
◼ Archived
Health
🔮 holds ✗
Millions of Metformin drug users issued serious four day warning
Millions of Metformin users and patients on other common medications face serious health warnings amid extreme heat hitting England and Wales.
◼ Archived
Business
🔮 fades ✓
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
◼ Archived
Business
🔮 fades ✓
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is reportedly nearing an $11 billion acquisition of biotech firm Apogee Therapeutics to secure an experimental eczema treatment.